Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma [scRNA-seq]

ABSTRACT: Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma [scRNA-seq]

PROVIDER: PRJNA1265191 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR33633692_1.fastq.gz	Fastqsanger.gz
	SRR33633692_2.fastq.gz	Fastqsanger.gz
	SRR33633693_1.fastq.gz	Fastqsanger.gz
	SRR33633693_2.fastq.gz	Fastqsanger.gz
	SRR33633694_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 14

Similar Datasets

Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma

Project description:To investigate the effects of the I/IIb HDAC inhibitor, Purinostat Mesylate (PM, also called HL13) on gene expression in multiple myeloma. The MM.1S cells were treated with Ctrl (DMSO) or HL13 (5nM) for 24 hours. Then the cells were collected and total RNA were isolation by Trizol. The expression profiling by array generated following the recommended protocol of Affymetrix GeneChip Human Transcriptome Array 2.0. To investigate the effects of the I/IIb HDAC inhibitor, Purinostat Mesylate (PM, also called HL13) on gene expression in multiple myeloma. The MM.1S cells were treated with Ctrl (DMSO) or HL13 (5nM) for 24 hours. Then the cells were collected and total RNA were isolation by Trizol. The expression profiling by array generated following the recommended protocol of Affymetrix GeneChip Human Transcriptome Array 2.0.

2025-07-01 | GSE296480 | GEO

Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma

Project description:Purinostat Mesylate (PM), a highly selective HDAC I/IIb inhibitor, exhibits excellent antitumor activity in multiple MM and lymphoma cell lines and multiple mouse models, outperforming the pan-HDAC inhibitor panobinostat or first-line/second-line multi-drug combinations. Different from panobinostat, bulk RNA-seq analysis results revealed that PM targeted essential tumor survival factors, and triggered inflammation and interferon responses. ScRNA-seq of 5TMM models further indicated that PM enhanced antitumor immunity by boosting monocyte- and T cell-mediated immune responses.

2025-05-15 | GSE296835 | GEO

Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma [PDX]

2025-05-15 | GSE296833 | GEO

Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma [scRNA-seq]

2025-05-23 | GSE297562 | GEO

Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma

Project description:Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma

| PRJNA1259464 | ENA

Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma

Project description:Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma

| PRJNA1261787 | ENA

Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma [PDX]

Project description:Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma [PDX]

| PRJNA1261791 | ENA

Genomic Analysis of Relapsed/Refractory DLBCL

Project description:Genomic Analysis of Relapsed/Refractory DLBCL

| PRJNA1200817 | ENA

Genomic Analysis of Relapsed/Refractory DLBCL

Project description:Genomic Analysis of Relapsed/Refractory DLBCL

| PRJNA1200818 | ENA

DNA methylation of Relapsed/Refractory AML

Project description:DNA methylation of Relapsed/Refractory AML

| PRJNA934390 | ENA